



# **King's Research Portal**

DOI: 10.1016/j.jaut.2016.05.005

Document Version Peer reviewed version

Link to publication record in King's Research Portal

Citation for published version (APA):

Liberal, R., Grant, C. R., Ma, Y., Csizmadia, E., Jiang, Z. G., Heneghan, M. A., Yee, E. U., Mieli-Vergani, G., Vergani, D., Robson, S. C., & Longhi, M. S. (2016). CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. *Journal of Autoimmunity*, *72*(0), 102-112. https://doi.org/10.1016/j.jaut.2016.05.005

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

#### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal

#### Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

## Table 1. Demographic and laboratory data

	Number of subjects	Sex (F/M):	Age (years):	AST (nv<50IU/l)	GGT (nv<55IU/l)	Bilirubin (nv<20µmol/l)	<b>IgG</b> (nv 6.5-17 g/l)	Autoantibody Titer*		
								ANA	SMA	LKM-1
AILD	38	17/21	0.1-34.1 (15.2)							
Active patients <sup>†</sup>	12	5/7	3.6-30.2 (14.6)	55-2462 (100)	143 (27-883)	12-257 (31)	8.5-44.3 (19.1)	0-160 (20)	0-1280 (10)	neg
Remission patients	26	12/14	0.1-34.1 (15.6)	11-49 (23)¶	$7-223 \ (17.5)^{\infty}$	3-26 (9) <sup>§</sup>	6.4-29.9 (12.6) <sup>‡</sup>	0-20 (0)	0-80 (0)	neg

Data presented as range (median) unless noted otherwise; nv: normal value

AILD: autoimmune liver disease

<sup>†</sup>: including five patients at disease presentation

AST: aspartate aminotransferase

GGT: gamma glutamyl transferase

IgG: immunoglobulin G \*: Autoantibody titer shown as reciprocal

ANA: anti-nuclear antibody

SMA: smooth muscle antibody

LKM-1: liver kidney microsomal antibody type 1

 $^{\$}P=0.006$ ,  $^{\circ}P=0.009$ ,  $^{\$}P<0.001$ ,  $^{\$}P=0.01$  when comparing AST, GGT, bilirubin and IgG levels between patients with active disease and at remission